Nautilus Biotechnology, Inc. (NAUT) 10-Year Financial Performance & Capital Metrics

NAUT • • Industrial / General

HealthcareBiotechnologyPlatform & Technology CompaniesDiagnostics & Immune Monitoring

AboutNautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.Show more

Revenue $0
EBITDA -$75M -1.1%
Net Income -$71M -11.2%
EPS (Diluted) -0.56 -9.8%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -29.86% -36.1%
ROIC -24.83% -11.2%
Debt/Equity 0.15 +11.9%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 95 (top 5%)
✓Trading at only 1.1x book value

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM10.53%

EPS CAGR

10Y-

5Y-

3Y-

TTM10.71%

ROCE

10Y Avg-30.49%

5Y Avg-24.9%

3Y Avg-23.92%

Latest-30.66%

Peer Comparison

Diagnostics & Immune Monitoring

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TECHBio-Techne Corporation	10.9B	69.96	152.09	5.23%	6.41%	3.97%	2.35%	0.23
SPRYARS Pharmaceuticals, Inc.	1.1B	11.09	142.00	2970.63%	-56.06%	-54.21%	1.18%	0.00
VCYTVeracyte, Inc.	3.24B	41.00	132.26	23.46%	6.12%	2.41%	1.97%	0.04
CSBRChampions Oncology, Inc.	99.56M	7.17	21.73	13.54%	4.32%	59.65%	7.03%	1.62
MDXGMiMedx Group, Inc.	851.59M	5.75	20.54	8.52%	10.38%	17.09%	7.58%	0.13
LTRNLantern Pharma Inc.	39.26M	3.51	-0.00			-197.36%		0.01
SEERSeer, Inc.	107.44M	1.91	-1.37	-8.13%	-486.02%	-29.19%		0.08
IMDXInsight Molecular Diagnostics Inc.	189.76M	6.62	-1.42	25.15%	-13.81%	-14.81%

Profit & Loss

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-
Cost of Goods Sold+	0	0	2.35M	2.84M	3.42M	5.71M	6.35M
COGS % of Revenue	-	-	-	-	-	-	-
Gross Profit+	0	0	-2.35M	-2.84M	-3.42M	-5.71M	-6.35M
Gross Margin %	-	-	-	-	-	-	-
Gross Profit Growth %	-	-	-	-0.21%	-0.2%	-0.67%	-0.11%
Operating Expenses+	111.68M	10.11M	13.4M	47.66M	60.2M	70.45M	75.12M
OpEx % of Revenue	-	-	-	-	-	-	-
Selling, General & Admin	111.68M	1.62M	3.31M	21.15M	23.75M	28.9M	31M
SG&A % of Revenue	-	-	-	-	-	-	-
Research & Development	0	8.49M	10.09M	26.51M	36.45M	47.25M	50.48M
R&D % of Revenue	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	-5.71M	-6.35M
Operating Income+	-111.68M	-10.11M	-15.74M	-50.5M	-63.62M	-76.15M	-81.48M
Operating Margin %	-	-	-	-	-	-	-
Operating Income Growth %	-	0.91%	-0.56%	-2.21%	-0.26%	-0.2%	-0.07%
EBITDA+	626.6M	-9.56M	-13.4M	-47.66M	-60.2M	-74.3M	-75.12M
EBITDA Margin %	-	-	-	-	-	-	-
EBITDA Growth %	-	-1.02%	-0.4%	-2.56%	-0.26%	-0.23%	-0.01%
D&A (Non-Cash Add-back)	738.28M	548K	2.35M	2.84M	3.42M	1.85M	6.35M
EBIT	-111.68M	-10.11M	-15.62M	-50.31M	-57.92M	-76.15M	-70.78M
Net Interest Income+	0	0	0	329K	0	12.55M	10.78M
Interest Income	0	0	0	329K	5.82M	12.55M	10.78M
Interest Expense	0	0	0	0	5.82M	0	0
Other Income/Expense	738.28M	492K	125K	183K	5.69M	12.48M	10.7M
Pretax Income+	626.6M	-9.62M	-15.62M	-50.31M	-57.92M	-63.67M	-70.78M
Pretax Margin %	-	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%
Net Income+	626.6M	-9.62M	-15.62M	-50.31M	-57.92M	-63.67M	-70.78M
Net Margin %	-	-	-	-	-	-	-
Net Income Growth %	-	-1.02%	-0.62%	-2.22%	-0.15%	-0.1%	-0.11%
Net Income (Continuing)	626.6M	-9.62M	-15.62M	-50.31M	-57.92M	-63.67M	-70.78M
Discontinued Operations	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0
EPS (Diluted)+	87.18	-1.59	-0.47	-0.60	-0.46	-0.51	-0.56
EPS Growth %	-	-1.02%	0.7%	-0.28%	0.23%	-0.11%	-0.1%
EPS (Basic)	87.18	-1.59	-0.47	-0.60	-0.46	-0.51	-0.56
Diluted Shares Outstanding	7.19M	6.07M	33.07M	84.46M	124.59M	124.92M	125.43M
Basic Shares Outstanding	7.19M	6.07M	33.07M	84.46M	124.59M	124.92M	125.43M
Dividend Payout Ratio	-	-	-	-	-	-	-

Balance Sheet

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	1.33M	16.96M	77.66M	349.22M	187.21M	176.84M	132.83M
Cash & Short-Term Investments	144.49B	16.66M	76.74M	345.73M	184.47M	173.42M	129.89M
Cash Only	1.2M	595K	36.61M	185.62M	114.52M	19.4M	27.65M
Short-Term Investments	144.49B	16.06M	40.13M	160.11M	69.95M	154.02M	102.25M
Accounts Receivable	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-
Other Current Assets	-144.49B	0	0	0	0	3.42M	2.93M
Total Non-Current Assets+	144.49M	1.58M	7.35M	49.23M	162.84M	128.73M	109.92M
Property, Plant & Equipment	0	1.12M	6.21M	31.86M	32.57M	36.9M	32.33M
Fixed Asset Turnover	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0
Long-Term Investments	144.49M	0	0	16.37M	129.17M	90.65M	76.41M
Other Non-Current Assets	0	459K	1.14M	997K	1.11M	1.18M	1.18M
Total Assets+	145.82M	18.54M	85.01M	398.45M	350.05M	305.56M	242.74M
Asset Turnover	-	-	-	-	-	-	-
Asset Growth %	-	-0.87%	3.58%	3.69%	-0.12%	-0.13%	-0.21%
Total Current Liabilities+	5K	490K	3.02M	5.81M	6.79M	9.12M	7.63M
Accounts Payable	0	289K	470K	1.72M	1.27M	1.64M	987K
Days Payables Outstanding	-	-	73.12	221.29	135.91	104.86	56.71
Short-Term Debt	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0
Other Current Liabilities	5K	77K	617K	388K	438K	2.97M	2.55M
Current Ratio	266.45x	34.62x	25.73x	60.09x	27.57x	19.39x	17.40x
Quick Ratio	266.45x	34.62x	25.73x	60.09x	27.57x	19.39x	17.40x
Cash Conversion Cycle	-	-	-	-	-	-	-
Total Non-Current Liabilities+	5M	275M	111.71M	29.06M	28.34M	31.09M	26.38M
Long-Term Debt	5M	275M	0	0	0	0	0
Capital Lease Obligations	0	0	3.3M	29.06M	28.34M	31.09M	26.38M
Deferred Tax Liabilities	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	108.42M	0	0	0	0
Total Liabilities	140.82M	490K	114.73M	34.87M	35.13M	40.21M	34.01M
Total Debt+	5M	275M	4.78M	30.03M	30.33M	34.63M	30.48M
Net Debt	3.8M	274.4M	-31.83M	-155.59M	-84.19M	15.23M	2.83M
Debt / Equity	1.00x	15.23x	-	0.08x	0.10x	0.13x	0.15x
Debt / EBITDA	0.01x	-	-	-	-	-	-
Net Debt / EBITDA	0.01x	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-10.94x	-	-
Total Equity+	5M	18.05M	-29.72M	363.58M	314.92M	265.35M	208.73M
Equity Growth %	-	2.61%	-2.65%	13.23%	-0.13%	-0.16%	-0.21%
Book Value per Share	0.70	2.98	-0.90	4.30	2.53	2.12	1.66
Total Shareholders' Equity	5M	18.05M	-29.72M	363.58M	314.92M	265.35M	208.73M
Common Stock	0	1K	1K	12K	12K	13K	13K
Retained Earnings	626.6K	-14.71M	-30.32M	-80.64M	-138.56M	-202.24M	-273.02M
Treasury Stock	0	0	0	0	0	0	0
Accumulated OCI	0	7K	3K	-184K	-1.85M	-255K	57K
Minority Interest	0	0	0	0	0	0	0

Cash Flow

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-238.3M	-9.66M	-14M	-39.24M	-45.81M	-51.71M	-59.15M
Operating CF Margin %	-	-	-	-	-	-	-
Operating CF Growth %	-	0.96%	-0.45%	-1.8%	-0.17%	-0.13%	-0.14%
Net Income	626.6M	-9.62M	-15.62M	-50.31M	-57.92M	-63.67M	-70.78M
Depreciation & Amortization	0	548K	2.35M	2.84M	3.42M	5.71M	6.35M
Stock-Based Compensation	0	110K	369K	7.93M	10.38M	12.14M	12.7M
Deferred Taxes	0	0	0	0	0	0	0
Other Non-Cash Items	-866.23M	-157K	295K	320K	-890K	-2.66M	-1.96M
Working Capital Changes	1.33M	-545K	-1.39M	-22K	-788K	-3.22M	-5.46M
Change in Receivables	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0
Change in Payables	0	0	123K	1.26M	-561K	393K	-578K
Cash from Investing+	1.2M	4.05M	-25.28M	-138.96M	-25.74M	-43.73M	66.25M
Capital Expenditures	0	-926K	-921K	-2.27M	-2.32M	-2.44M	-2.12M
CapEx % of Revenue	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-
Other Investing	1.2M	4.98M	0	0	0	0	154.65M
Cash from Financing+	145.19B	36K	75.9M	327.45M	562K	368K	1.14M
Debt Issued (Net)	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-
Other Financing	145.19B	36K	42K	335.41M	0	0	0
Net Change in Cash	-	-	-	-	-	-	-
Free Cash Flow+	-238.3M	-10.59M	-14.92M	-41.51M	-48.13M	-54.15M	-61.27M
FCF Margin %	-	-	-	-	-	-	-
FCF Growth %	-	0.96%	-0.41%	-1.78%	-0.16%	-0.13%	-0.13%
FCF per Share	-33.15	-1.75	-0.45	-0.49	-0.39	-0.43	-0.49
FCF Conversion (FCF/Net Income)	-0.38x	1.00x	0.90x	0.78x	0.79x	0.81x	0.84x
Interest Paid	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0

Key Ratios

Metric	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	12532%	-83.45%	-	-30.14%	-17.07%	-21.95%	-29.86%
Return on Invested Capital (ROIC)	-	-5.03%	-10.23%	-51.73%	-21.75%	-22.34%	-24.83%
Debt / Equity	1.00x	15.23x	-	0.08x	0.10x	0.13x	0.15x
Interest Coverage	-	-	-	-	-10.94x	-	-
FCF Conversion	-0.38x	1.00x	0.90x	0.78x	0.79x	0.81x	0.84x

Frequently Asked Questions

Growth & Financials

Nautilus Biotechnology, Inc. (NAUT) grew revenue by 0.0% over the past year. Growth has been modest.

Nautilus Biotechnology, Inc. (NAUT) reported a net loss of $62.8M for fiscal year 2024.

Dividend & Returns

Nautilus Biotechnology, Inc. (NAUT) has a return on equity (ROE) of -29.9%. Negative ROE indicates the company is unprofitable.

Nautilus Biotechnology, Inc. (NAUT) had negative free cash flow of $53.9M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener